Vascular Changes After Intra-bleb Injection of Bevacizumab
Michael Coote, Jonathan B. Ruddle, Queena Qin, Jonathan G. Crowston
Abstract
Michael Coote, Jonathan B. Ruddle, Queena Qin, Jonathan G. Crowston
Abstract
PURPOSE: To illustrate changes in bleb vascularity after subconjunctival bevacizumab injection. METHODS: Longitudinal changes in bleb vascularity were followed over 6 months pre and postbevacizumab injection. RESULTS: Bleb vascularity associated with increased scarring activity was observed 10 days postcataract surgery in an eye that had undergone trabeculectomy 3 months previously. A single subconjunctival avastin injection led to a dramatic reduction in bleb vascularity for 6 weeks. With continued steroids, a diffuse, healthy, well functioning bleb with minimal scar tissue was present at 6 months. CONCLUSIONS: Subconjunctival injection of bevacizumab reduced bleb vascularity and may provide an adjunct to current antifibrosis therapy. Further studies to establish the effect of bevacizumab on postoperative scaring are warranted.
OpenAlex reports 44 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
PURPOSE: To illustrate changes in bleb vascularity after subconjunctival bevacizumab injection. METHODS: Longitudinal changes in bleb vascularity were followed over 6 months pre and postbevacizumab injection. RESULTS: Bleb vascularity associated with increased scarring activity was observed 10 days postcataract surgery in an eye that had undergone trabeculectomy 3 months previously. A single subconjunctival avastin injection led to a dramatic reduction in bleb vascularity for 6 weeks. With continued steroids, a diffuse, healthy, well functioning bleb with minimal scar tissue was present at 6 months. CONCLUSIONS: Subconjunctival injection of bevacizumab reduced bleb vascularity and may provide an adjunct to current antifibrosis therapy. Further studies to establish the effect of bevacizumab on postoperative scaring are warranted.
Key concepts: Vascularity, Bleb (medicine), Medicine, Trabeculectomy, Bevacizumab, Glaucoma, Ophthalmology, Surgery